Expansion Of The Genetic Surveillance State: Taking The Blood Of Babies Born To Mississippi Teens
By Kashmir Hill,
Forbes
| 07. 02. 2013
In what sounds like a plot twist from a dystopic-future novel, Mississippi
is now requiring hospitals to store the blood of babies born to mothers 16 and younger. The
new law, which went into effect on Monday, July 1, is meant to discourage teen pregnancy, according to its drafters, but in a very roundabout way.
Any time a teen mom doesn’t know who the father is, or won’t say who the father is, or says the father is over 21, a hospital is required to take a blood sample from the baby’s umbilical cord and put it on ice. DNA will then be extracted from that blood and used to hunt down the (presumably) older men who had sex with the young women. They can be charged with statutory rape if they are more than 3 years older than the under-16 moms. The state hopes this will discourage cradle-robbers/cradle-makers in the future.
Via
NPR:
Starting in July, doctors and midwives in the state will be required by law to collect samples of umbilical cord blood from babies born...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...